title: Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases.
abstract: BACKGROUND
  The purpose of this study was to determine the incidence, risk factors and prognostic impact of anaemia and thrombocytopenia in patients with bone metastases (BM) from prostate cancer.
  
  
  METHODS
  Retrospective cohort study including 51 consecutive patients treated at a community hospital. Twenty-nine patients (57%) received taxotere after diagnosis of BM.
  
  
  RESULTS
  Haemoglobin (Hb) < or = 12.0 g/dL at BM detection was associated with shorter overall survival. During follow-up, 25 patients (49%) experienced episodes with Hb < 10 g/dL unrelated to side effects of cancer therapy. Fifteen patients required red blood cell transfusion. Median time from diagnosis of BM to Hb < 10 g/dL was 23 months. Median survival from Hb < 10 g/dL was 5.4 months. There was no factor predicting for Hb < 10 g/dL. Five patients (10%) developed thrombocyte (Trc) count <50 x 10(9)/L. All of these had previously received blood transfusion. Median interval from Hb < 10 g/dL to Trc < 50 x 10(9)/L was 2.5 months. Survival after thrombocytopenia was short (3 weeks to 4 months). Haematuria and subdural haematoma were among the causes of death.
  
  
  CONCLUSIONS
  We found high rates of significant bone marrow failure in treatment-refractory patients. Both Hb < 10 g/dL and Trc < 50 x 10(9)/L predict for unfavourable survival.
authors.affiliation: Department of Internal Medicine - Division of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway. cnied@hotmail.com
authors.forename: Carsten
authors.initials: C
authors.lastname: Nieder
authors.forename: Ellinor
authors.initials: E
authors.lastname: Haukland
authors.forename: Adam
authors.initials: A
authors.lastname: Pawinski
authors.forename: Astrid
authors.initials: A
authors.lastname: Dalhaug
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000097:blood / Q000209:etiology* / Q000401:mortality / Q000628:therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy / Q000401:mortality / Q000556:secondary*; D000077143:Docetaxel; D017707:Erythrocyte Transfusion; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D015994:Incidence; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009664:Norway; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology*; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D043823:Taxoids / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000097:blood / Q000209:etiology* / Q000401:mortality / Q000628:therapy; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D006454:Hemoglobins; D043823:Taxoids; D000077143:Docetaxel